Abstract
Nineteen patients with glioblastoma were treated with nicotinamide and carbogen and radiotherapy. Eight patients did not complete the protocol because of hepatic toxicity from phenytoin/nicotinamide drug interactions, persistent nausea or vomiting with nicotinamide, intolerance of the carbogen breathing apparatus, or other reason. In addition, early radiation neurotoxicity appeared increased.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Administration, Inhalation
-
Administration, Oral
-
Adolescent
-
Adult
-
Aged
-
Animals
-
Carbon Dioxide / administration & dosage
-
Carbon Dioxide / adverse effects*
-
Carbon Dioxide / therapeutic use
-
Combined Modality Therapy
-
Drug Tolerance
-
Female
-
Glioblastoma / diagnosis
-
Glioblastoma / drug therapy*
-
Glioblastoma / radiotherapy*
-
Humans
-
Liver / drug effects*
-
Male
-
Middle Aged
-
Niacinamide / administration & dosage
-
Niacinamide / adverse effects*
-
Niacinamide / therapeutic use
-
Oxygen / administration & dosage
-
Oxygen / adverse effects*
-
Oxygen / therapeutic use
-
Prospective Studies
-
Radiotherapy Dosage
-
Rats
-
Treatment Outcome
Substances
-
Carbon Dioxide
-
Niacinamide
-
carbogen
-
Oxygen